The present invention provides a process for the preparation of crystalline anhydrous compound of Formula (X), Further, the present invention relates to the use of compound of Formula (X) preparation of Raltegravir (I) or its pharmaceutically acceptable salt thereof.
本发明提供了一种制备结晶无
水式(X)化合物的工艺,此外,本发明还涉及使用式(X)化合物制备
雷特格韦(I)或其药学上可接受的盐。